Acute myeloid leukemia drugmaker closes $14.2M, focuses on personalized medicine
from MedCity News
Tolero Pharmaceuticals, a Salt Lake City, Utah drug developer, has set its sights on ramping up the commercialization and development efforts of its acute myeloid leukemia treatment, which will enter phase 3 trial sometime next year. The company’s fresh off of closing a series B round of $14.2 million, though the initial aim for the company was to raise $35 million.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063